

2nd December 2014

The ASX Market Announcements Platform ASX Limited

By E-lodgement

ASX Announcement

CHANGE OF COMPANY NAME

We advise that the Company has changed its name to Prescient Therapeutics Limited and is expected to start trading as ASX code "PTX" on 15 December 2014.

Yours faithfully

Sean Henbury

Company Secretary

Ends.

For further information contact:

Mr. Rudi Michelson

Monsoon Communications

Ph: +61 (0) 3 9620 3333

Dr Rob Crombie

Managing Director

Prescient Therapeutics Limited

Ph: +61 (0) 3 9982 4563

About Prescient Therapeutics

Prescient Therapeutics Limited is a clinical stage oncology company currently engaged in the development of novel products for the treatment of cancer. It holds an exclusive worldwide license to the novel cancer compound GGTI-2418 for the treatment of multiple myeloma, breast and pancreatic cancer. GGTI-2418 is expected to enter Phase 1b/2 clinical trials in breast cancer and multiple myeloma in early 2015.

Prescient Therapeutics has also obtained shareholder approval to acquire oncology company AKTivate Therapeutics and its novel TCN-P cancer drug. The Company's technology inhibits the highly promising drug target AKT and includes two active clinical trials – a Phase 1b/2 in breast cancer and an active Phase 1b in ovarian cancer. These trials are funded by US government authorities including grants from the Department of Defence and National Cancer Institute.

In addition, the Company has granted a license to major French biotechnology company Transgene for access to its Co-X-Gene™ technology for use in two of Transgene's immunotherapeutic products.